LUND, SWEDEN / ACCESSWIRE / August 9, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported progress in the ongoing phase I clinical trial of CAN10. The independent data monitoring committee has reviewed unblinded data from study participants in the ongoing single dose part of the trial and recommended continuation to the next phase, multiple dosing in participants with psoriasis, planned to start during Aug 2024. In addition, new pharmacodynamic biomarker results from the study confirm that CAN10 potently inhibits the activity of inflammatory immune cells after a single dose.
LUND, SE / ACCESSWIRE / June 20, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today announced that nadunolimab (CAN04) combination therapy results in advanced/metastatic pancreatic cancer (PDAC) will be presented at ESMO Gastrointestinal Cancer Congress 2024 in Munich June 26-29. Efficacy in the 73 patients treated was better than expected for chemotherapy only based on historical data. Strongest efficacy was observed in patients with high tumor levels of IL1RAP, the target of nadunolimab, with median survival (OS) of 14.2 months. Notable new data highlight the relevance of tumor promoting KRAS mutations and correlations of nadunolimab's mechanism of action, further arguing for nadunolimab as a therapy of PDAC.
LUND, SE / ACCESSWIRE / June 14, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; NasdaqStockholm:CANTA) today reported progress in the ongoing phase 1 clinical trial of the CAN10 antibody. Seven dose groups have now been concluded without any safety concerns. Furthermore, additional receptor occupancy studies confirm that CAN10 saturates its target molecule, IL1RAP, on immune cells from the study participants. The study follows timelines with the next dose group starting immediately, followed by the first group investigating multiple dosing, planned to start during Q3.
LUND, SE / ACCESSWIRE / June 11, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA), today announced the strengthening of its management team through the recruitment of Ton Berkien as Chief Business Officer. At Cantargia, he will be responsible for business development efforts and continue to maintain and foster relationships with leading pharmaceutical and biotechnology companies. Ton has a solid background through approximately 30 years in pharma, biotech, investment and consulting with significant experience in business development. He will commence his role October 1, 2024
LUND, SWEDEN / ACCESSWIRE / May 23, 2024 / Cantargia's (STO:CANTA) Annual General Meeting on 23 May 2024 resolved in accordance with the following:
LUND, SE / ACCESSWIRE / May 21, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced its interim report for the first quarter of 2024.
LUND, SWEDEN / ACCESSWIRE / May 7, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) will publish the company's interim report for the first quarter 2024 on Tuesday, May 21, 2024, at 07:00 a.m. CEST.
LUND, SWEDEN / ACCESSWIRE / April 18, 2024 / Cantargia (STO:CANTA) The shareholders of Cantargia AB (publ) are invited to the annual general meeting on Thursday, 23 May 2024, at 15.00 CEST at Ideon Gateway, Scheelevägen 27, Lund, Sweden.
LUND, SE / ACCESSWIRE / April 18, 2024 / Cantargia (STO:CANTA) nnCantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today announced that the annual report for 2023 has been published. The Annual Report and the European Single Electronic Format (ESEF) report are attached to this press release and are available on the company's website, www.cantargia.com.
LUND, SE / ACCESSWIRE / April 17, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported publication of new preclinical data in the highly reputable scientific journal Cell Reports on the clinical stage antibody CAN10, specifying the precise interactions between CAN10 and its target IL1RAP and highlighting its functional capabilities to block multiple signaling pathways. These analyses explain the unique properties that makes CAN10 a potent blocker of the disease-promoting inflammatory cytokines IL-1, IL-33 and IL-36. This mechanism could be of high value in the treatment of a large number of diseases.